Failed to import article template. Reason: Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Merck’s Keytruda receives European approval for two new indications in gynaecologic cancers: Rahway, New Jersey Friday, October 25, 2024, 09:00 Hrs [IST] Merck, known as MSD out ...

Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

Patients with TNBC and HR+/HER2- breast cancer demonstrated safe treatment with preoperative radiation therapy with Keytruda.

Findings seen in combination with chemotherapy following surgery in patients with curative intent. HealthDay News — Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in ...

Adding pembrolizumab to modern, high-quality chemoradiotherapy significantly improved overall survival in patients with locally advanced cervical cancer.

Merck's Keytruda now approved by European Commission for new gynecologic cancer indications, expanding its reach in the EU.

The European Commission (EC) has approved two new indications for Keytruda (pembrolizumab), Merck & Co’s anti-PD-1 therapy, ...

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...